Spot on sarcoma clinical trials (Bone Sarcomas, GIST, TGCT)

Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.

• SPAGN Member groups • Unsubscribe newsletter • Contact

Dear SPAGN Members and Friends,

Welcome to Part 2 of our Clinical Trials Update. In this issue, we focus on bone sarcomas, GIST and TGCT.

The SPAGN Study Directory brings together ongoing clinical trials from around the world in one place. It includes studies on soft tissue sarcomas, bone sarcomas, GIST, desmoid tumours, and TGCT, as well as links to national clinical trial registries maintained by trusted medical organisations.

👉 Explore the SPAGN Study Directory and discover ongoing clinical trials for sarcoma patients worldwide.

If you know of an ongoing clinical trial that is not yet included in the directory, we would be grateful if you could let us know (info@sarcoma-patients.org). Your feedback helps us keep this resource as comprehensive and up to date as possible.

With best wishes,

SPAGN Board of Directors & Team

Clinical trials for patients with bone sarcomas

Photo: Louis Reed on Unsplash

iEuroEwing: This is an European clinical trial to optimize current standard treatment for Ewing sarcoma patients. It evaluates the combination with Vinorelbin and cyclophosphamide, as well as the optimal radiation dose.
INBRX-109 In Ewing Sarcoma: The study assesses the safety, optimal dose, and preliminary effectiveness of INBRX-109, a novel therapeutic antibody, in patients with advanced or metastatic Ewing sarcomas.
rEECur: Compares four different therapy regimens to find out which is most effective and/or has fewest side effects, in patients with Ewing sarcoma that is not responding to treatment.
EMERGE 101: Assesses the safety, efficacy, and optimal dosing of lurbinectedin in pediatric and young adult patients with advanced Ewing sarcoma.

For ongoing studies about Ewing Sarcoma in Europe, please check the list of the EuroEwing Consortium which is updated on a regular basis.

Clinical trials for patients with GIST

StrateGIST 3: Compares the safety and efficacy of Velzatinib (IDRX-42) with sunitinib in adult patients with GIST, after first-line treatment with imatinib.
POLARIS-3: A Study of Olverembatinib in SDH-deficient GIST: POLARIS-3 is a Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient GIST (China only)

TGCT Patient Preference Study

TGCT preference research study: This study invites people living with TGCT and the clinicians treating them to share their experiences, priorities and treatment preferences. The results will help regulators better understand what matters most to the TGCT community when evaluating future treatments.

Sarcoma Patient Advocacy Global Network e.V./Assoc.,

Untergasse 36,

61200 Wölfersheim/Germany

E-Mail: info@sarcoma-patients.org